Emilie Lebraud

Emilie Lebraud

Auto-generated profile, based on publicly available information

Emilie Lebraud

Necker-Enfants Malades Institute, Université Paris Cité, INSERM U1151, CNRS UMR8253, Paris, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in The Journal of Pathology
Verified
Journal Article
Open access
LALéonie Albersammer
Léonie Albersammer
JLJuliette Leon
Juliette Leon
JMJelena Martinovic
Jelena Martinovic
JDJessy Dagobert
Jessy Dagobert
ELEmilie Lebraud
Emilie Lebraud
MRMarion Rabant
Marion Rabant
Chronic histiocytic intervillositis (CHI) is an inflammatory condition of the placenta, characterised by an abnormal, mainly macrophagic infiltrate within the intervillous space. Recent research suggests that CHI results from a ‘maternal‐foetal rejection’ mechanism, because at least some CHI cases fulfil the criteria for antibody‐mediated rejection (AMR) of kidney allografts according to the Banff classification [i.e. presence of anti‐human leukocyte antigen (HLA) paternal antibodies activating the complement or foetal‐specific antibodies (FSA), a macrophage‐rich infiltrate, and positive C4d immunostaining]. To gain further insights into CHI pathogenesis, we aimed to refine the phenotype of the inflammatory infiltrate using a multiplex immunofluorescence technique and to compare the mRNA signatures between CHI and AMR of kidney allografts. Twelve patients with C4d+ FSA+ CHI were included in the study and compared to a control group of 5 patients without inflammatory lesions on placental examination. We developed a multiplex immunofluorescence panel to identify CD4+ and CD8+ T lymphocytes, CD68+/CD206− and CD68+/CD206+ macrophages, and NK cells in the villi and intervillous space. Molecular signatures were studied using NanoString® technology and the B‐HOT panel recommended by the Banff classification for kidney allografts. Multiplex immunofluorescence revealed that the infiltrate in the intervillous space was mainly composed of CD68+/CD206− macrophages as well as a higher proportion of CD8+ lymphocytes in patients with CHI compared to controls. Densities of NK cells and CD4 T cells were very low. Molecular signatures showed an overexpression of HLA class II genes, an IFN‐γ signature, and cytokine gene sets in C4d+ FSA+ CHI patients, also involved in kidney AMR. These results reinforce the paradigm of maternal‐foetal rejection. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

25 July 2026 in Kidney International
Verified
Journal Article
Open access
ELEmilie Lebraud
Emilie Lebraud
OAOlivier Aubert
Olivier Aubert
LALaïla Aouni
Laïla Aouni
VGVirginia Garcia
Virginia Garcia
LMLise Morin
Lise Morin
DADany Anglicheau
Dany Anglicheau

10 January 2026 in bioRxiv
Verified
Preprint
Open access
ELEmilie Lebraud
Emilie Lebraud
OAOlivier Aubert
Olivier Aubert
LALaïla Aouni
Laïla Aouni
VGVirginia Garcia
Virginia Garcia
LMLise Morin
Lise Morin
DADany Anglicheau
Dany Anglicheau
Introduction: Antibody-mediated rejection (AMR) remains a leading cause of kidney allograft failure, with both HLA and non-HLA antibodies implicated in its pathogenesis. The contribution of non-HLA antibodies (non-HLA Abs) to microvascular inflammation (MVI) and graft outcome, particularly in cases lacking donor-specific anti-HLA antibodies (HLA-DSAs), remains incompletely understood. Methods: We analyzed 571 post-transplant serum samples from 326 patients with histological features of AMR (AMRh) and 164 stable controls. Non-HLA Abs were detected using the previously developed Non-HLA Antibody Detection Immunoassay (NHADIA), and associations were examined with histological lesions, AMRh persistence, and graft outcomes. Biopsies were scored according to Banff 2022 criteria, and patients were stratified by HLA-DSA and NHADIA status. Results: NHADIA values were significantly higher in AMRh patients compared to controls (P=0.0001), regardless of HLA-DSA status. NHADIA values correlated with the severity of glomerulitis, peritubular capillaritis and global MVI scores. In AMRh patients with HLA-DSAs, non-HLA Abs remained independently associated with MVI severity. Follow-up biopsies revealed persistent AMR lesions in patients with both HLA-DSAs and non-HLA Abs. Allograft survival was lowest in double-positive patients, and NHADIA positivity independently predicted graft loss (HR=2.25, 95% CI: 1.03–4.92, P=0.042). Incorporating NHADIA into the Banff classification reclassified 61% of AMRh cases as “double-positive AMRh,” and identified new subgroups with significant prognostic differences. Conclusion: Post-transplant detection of non-HLA antibodies identifies a distinct subset of AMR with more severe histology and worse graft prognosis, particularly when coexisting with HLA-DSAs. Integrating non-HLA Ab testing into current diagnostic frameworks may refine AMR classification and improve risk stratification. TRANSLATIONAL STATEMENT: This study highlights the clinical relevance of non-HLA antibodies, identified using our innovative endothelial cell-based assay (NHADIA), in kidney transplant recipients. Their presence is associated with more severe antibody-mediated rejection (AMR) and poorer graft outcomes, even in the absence of donor-specific HLA antibodies. Incorporating non-HLA antibody detection into routine post-transplant evaluation may allow clinicians to better identify high-risk patients, including those previously classified as DSA-negative AMR. This expanded immunological profiling refines AMR diagnosis, improves risk stratification, and opens new avenues for personalized immunosuppressive strategies, ultimately enhancing long-term graft survival and patient care.